Dr Reddy's Laboratories Ltd
drreddys.comWhat Do They Do?
Sells generic medicines and consumer health products for patients, and active ingredients and research services to pharmaceutical and biotechnology companies.
20-F for FY2026, filed May 29, 2026The global generics business has remained the largest contributor to revenues, with increased focus on complex products, injectables and…View ↗
This segment consists of our business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products…View ↗
. This segment primarily consists of our business of manufacturing and marketing active pharmaceutical ingredients and intermediates, also…View ↗
We provide niche service capabilities, technology platforms, and competitive cost structures to innovator and biotechnology companies.View ↗
How Do They Make Money?
Most revenue comes from goods: customers pay for finished medicines and ingredients when products are delivered or dispatched, depending on the sale. Research services are paid for as work is performed; licensing can bring upfront, milestone and royalty payments.
20-F for FY2026, filed May 29, 2026The Company’s revenue is derived from sales of goods, service income and income from licensing arrangements. Most of such revenue is…View ↗
Revenue is recognized when the control of the goods has been transferred to a third party. This is usually when the title passes to the…View ↗
Upon delivery or dispatch of products to customers, subject to the terms of the applicable contract.View ↗
Revenues include amounts derived from product out-licensing agreements. These arrangements typically consist of an initial up-front payment…View ↗
Royalty income earned through a license is recognized when the underlying sales have occurred.View ↗
Revenue from services rendered, which primarily relate to contract research, is recognized in the consolidated income statement as the…View ↗
INR 335.9B
-
20-F for FY2026, filed May 29, 2026
INR 335.9B ↗
Who Are Their Customers?
In India, generic medicines are delivered to distributors; strategic partners help sell in markets where Dr. Reddy’s lacks direct commercial presence. Innovator and biotechnology companies use its research services.
20-F for FY2026, filed May 29, 2026Sales of generic products in IndiaView ↗
Control is transferred upon delivery of products to distributors by clearing and forwarding agents of the Company.View ↗
We develop, manufacture, and market high‑quality generic medicines at affordable prices, with a focus on credible brands, first‑to‑market…View ↗
We provide niche service capabilities, technology platforms, and competitive cost structures to innovator and biotechnology companies.View ↗
Do Revenues Turn Into Profits?
Yes. It kept 12.8% of its revenue as net income in FY2026 and turned 10.0% of it into free cash flow.
How Are They Changing?
Growing. Revenue grew 57% in 4 years, from INR 214.4B in FY2022 to INR 335.9B in FY2026, about 12% a year.
Consumer health portfolio
The latest business description includes nicotine-replacement brands in consumer healthcare within the finished-products segment; the older description covers branded and generic finished medicines and biologics.
20-F for FY2023, filed Jun 13, 2023 20-F for FY2026, filed May 29, 2026This segment consists of our business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products…View ↗
Loading...
